Ivacaftor vs Tezacaftor / ivacaftor

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Cystic Fibrosis

Shared mechanism: CFTR · full Cystic Fibrosis pipeline

Ivacaftor · Kalydeco

Marketed by Vertex Pharmaceuticals

Approved in Cystic Fibrosissmall molecule
Partial signal

NCT00909532 · Phase 3 · completed

The study was randomized and quadruple-blinded, compared ivacaftor with placebo, and enrolled 167 participants; its objective primary endpoint, percent-predicted FEV1, was met with a statistically significant treatment difference. However, the supplied registry record does not report a power or sample-size calculation, so the trial receives a moderate grade despite its otherwise strong design.

Reported efficacy

Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo 0.1 percent of predicted volume (L) (Standard Error 2.1) | 150 mg Ivacaftor q12h 12.6 percent of predicted volume (L) (Standard Error 2.1) (met)

Result source: NCT00909727

Tezacaftor / ivacaftor · Symdeko

Marketed by Vertex Pharmaceuticals

Approved in Cystic Fibrosissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: January 2027 · NCT03587961 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Cystic Fibrosis

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Tezacaftor / ivacaftor: registry results are on file for Cystic Fibrosis, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Ivacaftor
Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo -0.2 percent of predicted volume (L) (Standard Error 0.7) | 150 mg Ivacaftor q12h 10.4 percent of predicted volume (L) (Standard Error 0.7) NCT00909532 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo 0.1 percent of predicted volume (L) (Standard Error 2.1) | 150 mg Ivacaftor q12h 12.6 percent of predicted volume (L) (Standard Error 2.1) NCT00909727 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ivacaftor's landscape · Tezacaftor / ivacaftor's landscape